Targeting the MLL1 and/or the MLL4/KMT2D COMPASS complexes to reduce promoter or enhancer H3K4 methylation, respectively, impairs HR-positive breast cancer cell and tumor growth [33,36]. Here, KMT2D is linked to breast carcinoma.